PLRX vs. MRUS, DNLI, BHC, ZLAB, CPRX, GMTX, RXRX, HCM, TWST, and AMRX
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Merus (MRUS), Denali Therapeutics (DNLI), Bausch Health Companies (BHC), Zai Lab (ZLAB), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), Recursion Pharmaceuticals (RXRX), HUTCHMED (HCM), Twist Bioscience (TWST), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry.
Pliant Therapeutics vs.
Merus (NASDAQ:MRUS) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations.
Pliant Therapeutics has a net margin of 0.00% compared to Merus' net margin of -680.61%. Merus' return on equity of -38.89% beat Pliant Therapeutics' return on equity.
Merus has higher revenue and earnings than Pliant Therapeutics. Merus is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Merus presently has a consensus price target of $85.64, suggesting a potential upside of 117.08%. Pliant Therapeutics has a consensus price target of $40.50, suggesting a potential upside of 261.28%. Given Pliant Therapeutics' higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than Merus.
Merus received 278 more outperform votes than Pliant Therapeutics when rated by MarketBeat users. However, 74.26% of users gave Pliant Therapeutics an outperform vote while only 67.11% of users gave Merus an outperform vote.
96.1% of Merus shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 4.6% of Merus shares are owned by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Merus had 9 more articles in the media than Pliant Therapeutics. MarketBeat recorded 14 mentions for Merus and 5 mentions for Pliant Therapeutics. Merus' average media sentiment score of 0.75 beat Pliant Therapeutics' score of 0.54 indicating that Merus is being referred to more favorably in the media.
Merus has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Summary
Merus beats Pliant Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PLRX) was last updated on 1/18/2025 by MarketBeat.com Staff
